Abridge는 임상 대화를 구조화되고 청구 가능한 의료 기록으로 변환하는 엔터프라이즈급 생성형 AI 플랫폼입니다. 임상의의 번아웃을 줄이고, 문서 정확성을 향상시키며, 의료 시스템의 수익 주기 관리를 간소화하도록 설계되었습니다.
ScribeMD는 의료 전문가를 위해 설계된 HIPAA 준수 AI 의료 기록 도구입니다. 환자 상호 작용을 듣고, 전사하며, 구조화된 문서를 생성하여 임상 노트 작성을 자동화합니다. 이를 통해 의사는 행정 업무를 줄이고 환자당 상당한 시간을 절약하며 환자 치료에 더 집중할 수 있습니다.
제품 개요
Abridge 제품 개요
Abridge는 임상 대화를 구조화되고 청구 가능한 의료 기록으로 변환하는 엔터프라이즈급 생성형 AI 플랫폼입니다. 임상의의 번아웃을 줄이고, 문서 정확성을 향상시키며, 의료 시스템의 수익 주기 관리를 간소화하도록 설계되었습니다.
ScribeMD 제품 개요
ScribeMD는 의료 전문가를 위해 설계된 HIPAA 준수 AI 의료 기록 도구입니다. 환자 상호 작용을 듣고, 전사하며, 구조화된 문서를 생성하여 임상 노트 작성을 자동화합니다. 이를 통해 의사는 행정 업무를 줄이고 환자당 상당한 시간을 절약하며 환자 치료에 더 집중할 수 있습니다.
Detailed feature comparison
| Feature | Abridge | ScribeMD |
|---|---|---|
| 주요 카테고리 | 의료 보조원 | 의료 문서 |
| 등록일 | 2025-08-14 | 2025-08-10 |
| 가격 | 유료 | 유료 |
| 공식 사이트 | www.abridge.com | www.scribemd.ai |
| 제품 유형 | 웹사이트 | 웹사이트 |
| Performance data | ||
| 사용자 평점 | 확인되지 않음 | 확인되지 않음 |
| 댓글 | 0 | 0 |
| 월 방문 | 265.2K | 4.5K |
| 월 성장률 | 17.9% | 21.4% |
| 즐겨찾기 | 114 | 104 |
| Details | 상세 보기 | 상세 보기 |
Abridge vs ScribeMD monthly traffic
Compare Abridge and ScribeMD by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the Abridge vs ScribeMD monthly traffic comparison, Abridge currently shows 265.2K visits and ScribeMD shows 4.5K; Abridge has about 58.5 times the visible traffic of ScribeMD, an absolute difference of about 260.6K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Abridge monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 201.8K 월 방문
- 2026/1: 186K 월 방문
- 2026/2: 186.7K 월 방문
- 2026/3: 207.3K 월 방문
- 2026/4: 224.9K 월 방문
- 2026/5: 265.2K 월 방문
주요 지역
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 92.21% | 244.5K |
| 🇮🇳India | 2.53% | 6.7K |
| 🇻🇳Vietnam | 2.34% | 6.2K |
| 🇬🇧United Kingdom | 1.73% | 4.6K |
| 🇲🇽Mexico | 1.19% | 3.2K |
트래픽 소스
| Source type | Percentage | Traffic |
|---|---|---|
| 직접 | 94.36% | 250.2K |
| 리퍼럴 | 4.22% | 11.2K |
| 이메일 | 1.42% | 3.8K |
검색 키워드
ScribeMD monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 4.9K 월 방문
- 2026/1: 6K 월 방문
- 2026/2: 4.2K 월 방문
- 2026/3: 2K 월 방문
- 2026/4: 3.7K 월 방문
- 2026/5: 4.5K 월 방문
주요 지역
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 84.66% | 3.8K |
| 🇪🇸Spain | 14.21% | 644 |
| 🇮🇳India | 1.13% | 51 |
검색 키워드
Usage comparison
Compare the core capabilities of Abridge and ScribeMD
Abridge Core features
ScribeMD Core features
Use cases
Abridge Use cases
ScribeMD Use cases
Abridge vs ScribeMD:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth Abridge vs ScribeMD comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. Abridge is primarily listed under “의료 보조원”, while ScribeMD is primarily listed under “의료 문서”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (Abridge: 의료 보조원; ScribeMD: 의료 문서); Monthly visits (Abridge: 265.2K; ScribeMD: 4.5K); Monthly growth (Abridge: 17.9%; ScribeMD: 21.4%); Favorites (Abridge: 114; ScribeMD: 104); Website (Abridge: www.abridge.com; ScribeMD: www.scribemd.ai). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the Abridge vs ScribeMD monthly traffic comparison, Abridge currently shows 265.2K visits and ScribeMD shows 4.5K; Abridge has about 58.5 times the visible traffic of ScribeMD, an absolute difference of about 260.6K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
If public market visibility is an important first-pass criterion, investigate Abridge first. The final choice should still follow taxonomy, use case, and a real trial because higher traffic does not prove broader capabilities or better workflow fit.
Product positioning, use cases, and roles
Abridge and ScribeMD currently overlap in shared categories: 의료 문서 및 전사; shared tags: 임상 문서, EMR 자동화, HIPAA 준수 및 의료 전사. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
Abridge's unique categories/tags are 의료 보조원, 의료 AI, 임상의 소진, 생성형 AI, 의학 기록 및 수익 주기 관리; ScribeMD's are 자동화, 의사 생산성, 의료 AI, 의료 기록사, 환자 기록 및 음성 텍스트 변환. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
Abridge has no verified rating, 0 comments, 114 favorites, and 119 likes;ScribeMD has no verified rating, 0 comments, 104 favorites, and 124 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate Abridge first
Put Abridge on the priority trial list when the task aligns with “의료 보조원” and especially 의료 보조원, 의료 AI, 임상의 소진, 생성형 AI, 의학 기록 및 수익 주기 관리. This follows recorded positioning and does not imply unlisted capabilities are absent.
Abridge also currently records: pricing is paid, product type is website, 265.2K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate ScribeMD first
Put ScribeMD on the priority trial list when the task aligns with “의료 문서” and especially 자동화, 의사 생산성, 의료 AI, 의료 기록사, 환자 기록 및 음성 텍스트 변환. This follows recorded positioning and does not imply unlisted capabilities are absent.
ScribeMD also currently records: pricing is paid, product type is website, 4.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in Abridge and ScribeMD, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




